Mohanad Hamandi, MD

Week 1 of the fellowship is in the books. I’m extremely excited to be part of this incredible program and team of fellows. @MayoCVFellows @MayoClinic #CardioTwitter #MedTwitter

Full-body vs cerebral-only protection in TAVI-does it matter? The PROTECT H2H trial puts Emboliner head-to-head with Sentinel. Tune in to listen directly from @AdamGreenbaumMD @FITsOnTheGo @MayoClinicCV @emory_heart PROTECT The H2H: Emboliner vs. Sentinel Embolic Protection Devices in TAVR youtu.be/HjFwxNYEWDI?si… via @YouTube

Arab American Society of Cardiology second annual meeting 🫀🫀♥️

@AbdullahAlabcha @MayoClinicCV @MayoCVFellows @ACCmediacenter @ACCinTouch @AASC_Cardiology Congratulations, very well deserved

Honored to receive runner-up at the #ACC26 Young Investigator Award #YIA 🏆🫀 Grateful to @MohamadAlkhouli and the team @MayoClinicCV for their support and mentorship #CardioX #CardioTwitter #ACC26

Learned that building a procedural niche requires disciplined focus, while maintaining openness to adapt and expand the direction of both clinical practice and research. Thanks Dr Cohen for your time and insights @djc795 @MayoClinicCV @crfheart

Leadership team FITs On the Go #ACC26

Best senior resident & mentor on the block! ➡️ Go see @HamandiMd !!! 🤗

FITsOnTheGo is a @MayoClinicCV initiative led by fellows in training, featuring interviews with late-breaking trialists. Join us at the studio in the #ACC26 Learning Lounge, next to the Heart to Heart stage!

@benhibbertMDPhD @PietroDiSantoMD @MayoClinicCV @tjsimard @rebeccamathewmd @rajivxgulati @LewisHamilton @ScuderiaFerrari @UOHI @fdanielramirez Congratulations to the one and only @PietroDiSantoMD

Congratulations to @PietroDiSantoMD on successfully completing his PhD. Pietro joined the @MayoClinicCV family in January in the divisions of Interventional Cardiology and Critical Care Cardiology. During his training he published over 100 papers and his thesis on transradial access for pci just finished and his last project - an RCT on rivaroxaban for prevention of rao is complete. Thanks to Prof George Wells for supervising Pietro with me and getting him to the finish line. As is now tradition for all PhD grads a message from F1 and @RGrosjean. It took a long time but @PietroDiSantoMD got it done.

Today, the @MayoCVFellows were privileged to host @MKIttlesonMD as our annual Fellows' Visiting Professor. It was a day full of clinical gems, intense debate, and #kittlesonrules. Dr. Kittleson - thank you for joining us, and please come back soon to @MayoClinicCV @MayoClinic

I’m pleased to share that for the 8th consecutive year, Mayo Clinic is ranked the No. 1 hospital in the world by @Newsweek thanks to the extraordinary expertise, compassion, and commitment of our staff. rankings.newsweek.com/worlds-best-ho…

Contratulations @HamandiMd for this important contribution! MAC with mitral valve dysfunction and tricuspid regurgitation often coexist. It's important to study this as we enter the commercial era for TMVR in MAC with already 1 TMVR device (Tendyne) FDA approved for patients with MAC in 2025. Keep up the good work @MayoClinicCV !

@MayraGuerreroMD Thanks Dr Guerrero for your mentorship and support

Grateful for an incredible experience at #TCT2025 — from presenting our latest research to connecting with mentors and catching up with friends. Huge thanks to @TCTMD @crfheart @MayoClinicCV @MayoCVFellows

Once the forgotten, tricuspid valve is now the center of attention. TR is the most prevalent valvular heart disease among U.S. adults aged 65 to 85 years. #TCT2025 #PREVUEVALVE

@MayoClinicCV @MayoCVFellows @MayraGuerreroMD @pattypellikka @AbdullahAlabcha Here are the slides with more details. @MayraGuerreroMD

Presented our study on the prognostic impact of tricuspid regurgitation in patients with mitral annular calcification at TCT in San Francisco. Thanks Dr Guerrero and Dr Pellikka for your mentorship and support. @MayoClinicCV @MayoCVFellows @MayraGuerreroMD @pattypellikka

The movers & the shakers.. #TCTPlusMiddleEast team at the Moscone center preparing for the second iteration of the conference #InnovateDontReplicate Stay tuned for updates due for release this November @crfheart @TCTConference @jgranadacrf @djc795 @drptca @Dr_HaniNajm @AdelTash @kfaraidy @mmamas1973 @mirvatalasnag @AlkashkariWail

The best way to reduce atherosclerotic risk related to high TG is to get apoB to control (<70 mg/dL). Once that is done if TG are still high (> 500 mg/dL - pancreatitis risk) add high dose (4 gm) of omega 3 product or use fenofibrate if renal function is OK and patient not on coumadin. My bias is I prefer the fibrate due to its ability to reduce MACE when TG are high and for its microvascular benefits in a diabetic

A striking example of double-site obstruction in hypertrophic cardiomyopathy. The apical view demonstrates color Doppler flow acceleration in the LVOT with systolic anterior motion of the mitral valve during Valsalva. The CW Doppler reveals two distinct peaks — the first corresponding to the LVOT obstruction and the second to mid-ventricular obstruction. #ThingsFellowshipTaughtMe #CardioX #Cardiotwitter #echofirst @MayoCVFellows @jeffreygeske

LBBB EKG criteria include the absence of Q waves in leads I, V5, and V6. This helps distinguish true LBBB from a nonspecific intraventricular conduction delay. The loss of septal Q waves occurs because normal left-to-right septal depolarization is disrupted by the conduction block, eliminating the initial negative deflection (Q wave) in these leads. #ThingsFellowshipTaughtMe @MayoCVFellows #CardioX #cardiotwitter @MaanJokhadar